Class Action Lawsuit Filed Against GSK plc: Investors Encouraged to Contact Pomerantz LLP
NEW YORK, Feb. 25, 2025 – Pomerantz LLP, a leading national securities law firm, announces that a class action lawsuit has been filed against GSK plc (“GSK” or the “Company”) (NYSE: GSK). The lawsuit seeks to represent investors who purchased or otherwise acquired GSK securities between January 1, 2020, and February 23, 2025, inclusive (the “Class Period”).
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that:
- GSK was experiencing significant issues with its vaccine division, resulting in delays and production setbacks;
- GSK had underestimated the costs associated with these issues, leading to a significant reduction in earnings;
- GSK had failed to disclose material information regarding the impact of these issues on the Company’s financial statements;
As a result of these misrepresentations, GSK securities traded at artificially inflated prices during the Class Period. When the truth was revealed, the price of GSK securities declined significantly, causing investors substantial losses.
How This Affects Individual Investors
If you purchased or otherwise acquired GSK securities during the Class Period, you may be entitled to recover your losses. Investors who suffered losses on their GSK investments or have information relating to the fraudulent practices at GSK should contact Danielle Peyton at [email protected] or 646-581-9980, toll-free, Ext. 7925. You may also submit your information using the form on the firm’s website at
How This Affects the World
The impact of this lawsuit on the world may be significant, particularly in the pharmaceutical industry. GSK is a leading global healthcare company, and the allegations of fraudulent practices and production issues could damage the reputation of the industry as a whole. In addition, investors may become more cautious when investing in pharmaceutical companies, leading to decreased demand for securities and potentially lower stock prices.
The lawsuit also highlights the importance of transparency and accurate reporting in the securities industry. Companies that fail to disclose material information to investors can face significant consequences, including financial losses for investors and damage to their reputations.
Conclusion
The filing of a class action lawsuit against GSK plc is a significant development for investors in the Company’s securities. The allegations of fraudulent practices and production issues could result in substantial losses for investors, and the impact on the pharmaceutical industry and the securities industry as a whole could be significant. If you purchased or otherwise acquired GSK securities during the Class Period, it is important to contact Pomerantz LLP to discuss your potential recovery options.
At Pomerantz LLP, we are committed to fighting for the rights of investors. Our experienced securities lawyers have a proven track record of recovering damages for investors who have been victims of securities fraud. Contact us today to discuss your case.
This press release is a part of a series of press releases Pomerantz LLP has issued. The information contained in this press release is provided as a general announcement and for informational purposes only. It is not intended as a solicitation for claims that may not be valid under the applicable securities laws. The information contained herein may be subject to change without further notice.
Those who cannot attend the scheduled conference call are urged to pre-register on the call information website, which is available for all interested parties, so they will receive the call information the day before the call. For those unable to attend, a replay of the call will be available for up to 30 days after the call.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class action litigation. Founded in 1971, Pomerantz LLP pioneered the field of securities class action litigation and has since recovered numerous multimillion-dollar damages on behalf of investor clients.
